Net debt/EBITDA společnosti Beam Therapeutics
Jaká je hodnota metriky Net debt/EBITDA společnosti Beam Therapeutics?
Hodnota metriky Net debt/EBITDA společnosti Beam Therapeutics Inc. je 29.21
Jaká je definice metriky Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Beam Therapeutics
Čemu se věnuje společnost Beam Therapeutics?
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Firmy s metrikou net debt/ebitda podobnou společnosti Beam Therapeutics
- Hodnota metriky Net debt/EBITDA společnosti Strategic Metals je 29.05
- Hodnota metriky Net debt/EBITDA společnosti PCCW je 29.07
- Hodnota metriky Net debt/EBITDA společnosti PCCW je 29.07
- Hodnota metriky Net debt/EBITDA společnosti Atlantica Sustainable Infrastructure Plc je 29.10
- Hodnota metriky Net debt/EBITDA společnosti Barings BDC Inc je 29.12
- Hodnota metriky Net debt/EBITDA společnosti SANVO Fine Chemicals Ltd je 29.14
- Hodnota metriky Net debt/EBITDA společnosti Beam Therapeutics je 29.21
- Hodnota metriky Net debt/EBITDA společnosti Emera je 29.22
- Hodnota metriky Net debt/EBITDA společnosti Icade SA je 29.23
- Hodnota metriky Net debt/EBITDA společnosti Grocery Outlet Corp je 29.26
- Hodnota metriky Net debt/EBITDA společnosti Codexis je 29.27
- Hodnota metriky Net debt/EBITDA společnosti Altice Europe NV je 29.31
- Hodnota metriky Net debt/EBITDA společnosti Altice Europe N.V je 29.31